Patent details
300868
Product Name:
Ibrutinib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300868
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2529621
Status:
Refused Art. 10 of the EC Regulations
Application number:
300868
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)
Marketing Authorization
Marketing Authorization Number:
EU/1/14/945 - C(2015)4704
Marketing Authorization Type:
EEA
Marketing Authorization Date:
07/07/2015
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
29/03/2017
First Marketing Authorization date:
07/07/2015
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
31/03/2017
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
10/11/2020
Applicant/holder
From:
31/03/2017
Name:
Pharmacyclics LLC
Address:
995 East Arques Avenue, CA 94085, Sunnyvale, United States of America (US)
Agent
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
29/03/2017
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
VRV
Journal edition number:
46/20
Publication date:
11/11/2020
Description:
Lapse or annulment
2
Bulletin Heading:
SPC
Journal edition number:
14/17
Publication date:
05/04/2017
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date
Document type
Document Description
Number of pages
File Type
10/11/2020
Outgoing Correspondence
Decision refusal
3
PDF
/8/9/4/4/4/0800144498/docs/300868_7_376219l527a.pdf
28/07/2020
Outgoing Correspondence
Letter to applicant
3
PDF
/8/9/4/4/4/0800144498/docs/300868_9_356570l173.pdf
31/03/2017
Outgoing Correspondence
Confirmation receipt request
1
PDF
/8/9/4/4/4/0800144498/docs/300868_8_128736l174.pdf
29/03/2017
SPC Documents
Annex SPC
3
PDF
/8/9/4/4/4/0800144498/docs/300868_0_supplprotectioncertificate20200902040405341.pdf
29/03/2017
SPC Documents
Marketing Authorization SPC
3
PDF
/8/9/4/4/4/0800144498/docs/300868_1_supplprotectioncertificate20170331100507823.pdf
29/03/2017
Application Form
First filed application form
2
PDF
/8/9/4/4/4/0800144498/docs/300868_2_applicationform20170331100507661.pdf
29/03/2017
SPC Documents
Annex SPC
2
PDF
/8/9/4/4/4/0800144498/docs/300868_3_supplprotectioncertificate20200902040606727.pdf
29/03/2017
SPC Documents
Annex SPC
2
PDF
/8/9/4/4/4/0800144498/docs/300868_4_supplprotectioncertificate20200902040021672.pdf
29/03/2017
SPC Documents
Accompanying letter SPC
1
PDF
/8/9/4/4/4/0800144498/docs/300868_5_supplprotectioncertificate20200902040822813.pdf
29/03/2017
SPC Documents
Summary of the characteristics of the product
20
PDF
/8/9/4/4/4/0800144498/docs/300868_6_supplprotectioncertificate20170331100508019.pdf